Indivior PLC (LON:INDV)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 1.54B |
| Revenue (ttm) | 905.57M +4.1% |
| Net Income | -47.99M |
| EPS | -0.37 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 12.94 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,726,430 |
| Average Volume | 704,436 |
| Open | 1,248.00 |
| Previous Close | 1,219.00 |
| Day's Range | 1,230.00 - 1,264.00 |
| 52-Week Range | 554.50 - 1,264.00 |
| Beta | 0.26 |
| RSI | 71.54 |
| Earnings Date | Jul 31, 2025 |
About Indivior
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX T... [Read more]
Full Company ProfileNews
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, ...
Indivior (INDV) Completes Move from UK to US, Listed on Nasdaq
Indivior (INDV) Completes Move from UK to US, Listed on Nasdaq
Indivior Announces Completion of Redomiciliation to the United States
RICHMOND, Va., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced completion of its redomiciliation from the United Kingdom to the United States.
HARBOR CAPITAL ADVISORS, INC. Buys 781 Shares of Indivior PLC (INDV)
HARBOR CAPITAL ADVISORS, INC. Buys 781 Shares of Indivior PLC (INDV)
Interesting INDV Put And Call Options For March 20th
Investors in Indivior PLC (Symbol: INDV) saw new options become available this week, for the March 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INDV opt...
Grail and Indivior PLC come out on top in Healthcare quant picks ahead of Q4 earnings
Take the Zacks Approach to Beat the Markets: Indivior, FIGS & Ulta Beauty in Focus
Zacks highlights how Indivior, FIGS and Ulta Beauty delivered outsized gains as its ranks, recommendations and focus lists beat a volatile market.
INDV: Analyst Raises Price Target to $48.00, Maintains Buy Rating | INDV Stock News
INDV: Analyst Raises Price Target to $48.00, Maintains Buy Rating | INDV Stock News
Indivior Issues FY 2026 Financial Guidance
(RTTNews) - Indivior PLC (INDV) on Thursday has shared its financial outlook for 2026, pointing to anticipated revenue growth and improved profit margins, largely thanks to SUBLOCADE.
Indivior Provides Full-Year 2026 Financial Guidance and Business Update
Total Net Revenue Expected in the Range of $1,125 million to $1,195 million Total SUBLOCADE ® Net Revenue Expected to be in the Range of $905 million to $945 million Non-GAAP Operating Expenses Expec...
Insider Buying: Barbara Ryan Acquires Shares of Indivior PLC
Insider Buying: Barbara Ryan Acquires Shares of Indivior PLC
This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table
Oregon-based Stonepine Capital Management reduced its Indivior stake by 250,000 shares in the third quarter. The overall position value fell by about $2.75 million from the previous period.
Indivior Announces Inclusion in the S&P SmallCap 600® Index
RICHMOND, Va. , Dec. 22, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) ("Indivior PLC" or the "Company") today announced that it will be added to the S&P SmallCap 600® index, effective today.
Indivior (INDV) Trial Shows Potential of SUBLOCADE in Reducing Opioid Use
Indivior (INDV) Trial Shows Potential of SUBLOCADE in Reducing Opioid Use
New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations
Both monthly maintenance doses (100 mg and 300 mg) improved opioid abstinence and were well-tolerated with no new safety signals identified. Post-hoc analyses indicated the 300-mg monthly maintenance ...
Why One Value Fund Has a $101 Million Bet on Indivior Stock Amid a 212% Surge
This fund just doubled down on a stock that’s suddenly delivering the earnings momentum it’s promised for years.
Indivior (INDV) Resolves Major Legal Issue, Outlook Remains Positive
Indivior (INDV) Resolves Major Legal Issue, Outlook Remains Positive
Indivior (INDV) Resolves DOJ Case with $295M Payment
Indivior (INDV) Resolves DOJ Case with $295M Payment
Indivior Concludes Legacy U.S. Department of Justice Matter
RICHMOND, Va. , Nov. 20, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) today announced the Company has concluded the legacy U.S. Department of Justice (DOJ) matter by paying in full the outstanding...
Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference
RICHMOND, Va. , Nov. 19, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ: INDV) today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference: Piper Sandler 37th Annual Hea...
INDV Crosses Above Average Analyst Target
In recent trading, shares of Indivior PLC (Symbol: INDV) have crossed above the average analyst 12-month target price of $30.80, changing hands for $31.19/share. When a stock reaches the target an ana...
Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine
Medicaid and commercially insured patients with high adherence to SUBLOCADE® experienced lower relapse rates and reduced healthcare resource utilization Adherence to SUBLOCADE was associated with lowe...
Indivior PLC 2025 Q3 - Results - Earnings Call Presentation
INDV: Piper Sandler Raises Price Target Amidst Positive Outlook | INDV Stock News
INDV: Piper Sandler Raises Price Target Amidst Positive Outlook | INDV Stock News
Indivior (INDV) Maintained as 'Buy' by HC Wainwright & Co. ...
Indivior (INDV) Maintained as 'Buy' by HC Wainwright & Co., Price Target Raised to $35 | INDV Stock News